Outpatient Epcoritamab as 2L in NTE R/R DLBCL
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMassachusetts General Hospital
About this trial
The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
Eligibility criteria
Qualifiers
Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
High grade B-cell lymphoma (HGBCL) with rearrangements of MYC and BCL2 and/or BCL6
HGBCL NOS
EBV+ DLBCL
Disqualifiers
Participant must not have used an investigational drug or approved systemic lymphoma therapy within 28 days preceding the first dose of study drug. Steroids for lymphoma disease control are permitted but must be stopped at least 7 days prior to the first dose of study drug.
Participants must not have received prior CD20/CD3 bispecific antibody.
Participants must not have received prior autologous or allogeneic stem cell transplant.
Participants must not have received prior anti-CD19 CAR T-cell therapy.
Trial design
Treatments tested in this trial
- Epcoritamab
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Genmab
Collaborator
Source ClinicalTrials.gov